peginterferon beta-1a

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 37/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Relapsing Multiple Sclerosis

Conditions

Relapsing Multiple Sclerosis

Trial Timeline

Apr 1, 2011 → Oct 1, 2015

NCT ID

NCT01332019

About peginterferon beta-1a

peginterferon beta-1a is a phase 3 stage product being developed by Biogen for Relapsing Multiple Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01332019. Target conditions include Relapsing Multiple Sclerosis.

What happened to similar drugs?

20 of 20 similar drugs in Relapsing Multiple Sclerosis were approved

Approved (20) Terminated (2) Active (0)

✅Rebif® + Rebif®MerckApproved

✅Interferon beta-1a (Rebif)MerckApproved

✅Interferon beta-1aMerckApproved

✅Cladribine 10 mg oral tabletMerckApproved

✅Rebif® (clone 484-39)MerckApproved

✅RebifMerckApproved

✅Fingolimod 0.5 mgNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02587065	Approved	Completed	Feb 3, 2016	Dec 21, 2017	Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT02230969	Pre-clinical	Completed	Nov 12, 2014	Jan 20, 2022	Relapsing Forms of Multiple Sclerosis
NCT01978652	Phase 1	Completed	Dec 1, 2013	Feb 1, 2014	Healthy
NCT01332019	Phase 3	Completed	Apr 1, 2011	Oct 1, 2015	Relapsing Multiple Sclerosis

Competing Products

20 competing products in Relapsing Multiple Sclerosis

See all competitors

Product	Company	Stage	Hype Score
Placebo + Pirtobrutinib	Eli Lilly	Phase 2	27
CT-P53 + US-Ocrevus + EU-Ocrevus	Celltrion	Phase 3	47
LY2127399 + Placebo	Eli Lilly	Phase 2	35
dirucotide + placebo	Eli Lilly	Phase 2/3	38
BIIB019 (Daclizumab High Yield Process) + Placebo	AbbVie	Phase 2	35
Daclizumab	AbbVie	Phase 3	32
BIIB019 (Daclizumab High Yield Process) + Placebo	AbbVie	Phase 2	35
BIIB019 (Daclizumab) + trivalent seasonal influenza vaccine	AbbVie	Phase 2	35
BIIB019 (Daclizumab)	AbbVie	Phase 3	32
BIIB019 (Daclizumab High Yield Process) + Interferon beta-1a Placebo + Interferon beta-1a + Daclizumab High Yield Process Placebo	AbbVie	Phase 3	40
Rebif (Interferon beta-1a)	Merck	Pre-clinical	26
Interferon beta-1a	Merck	Pre-clinical	26
Rebif New Formulation + prophylactic Ibuprofen + Rebif New Formulation + ibuprofen PRN	Merck	Phase 3	40
Rebif® + Avonex®	Merck	Phase 3	40
Rebif® + Rebif®	Merck	Approved	43
VigantOL oil plus interferon beta-1a (Rebif) + Placebo plus interferon beta-1a (Rebif) + Interferon beta-1a (Rebif®) alone	Merck	Phase 2	35
Placebo + IFN beta-1a + Methylprednisolone	Merck	Phase 2	27
Interferon beta-1a (Rebif)	Merck	Approved	43
Teriflunomide + Evobrutinib	Merck	Phase 3	32
Cladribine + Placebo + Microgynon®	Merck	Phase 1	29